business Finance healthcare mergers pharmaceuticals

BioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US Market

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the best stocks to buy under $20. On October 1, BioCryst Pharmaceuticals announced the successful completion of the previously announced sale of its European ORLADEYO (berotralstat) business to Neopharmed Gentili. The transaction is valued at $250 million upfront, subject to customary purchase price adjustments, with the potential for […]